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Abstract
Calcium phosphate (CaP) nanoparticles(NP) with an asymmetric lipid bilayer coating have been
designed for targeted delivery of siRNA to the tumor. An anionic lipid, dioleoylphosphatydic acid
(DOPA), was employed as the inner leaflet lipid to coat the nano-size CaP cores, which entrap the
siRNA, such that the coated cores were soluble in organic solvent. A suitable neutral or cationic
lipid was used as the outer leaflet lipid to form an asymmetric lipid bilayer structure verified by
the measurement of NP zeta potential. The resulting NP was named LCP-II with a size of about 25
to 30 nm in diameter and contained a hollow core as revealed by TEM imaging. PEGylation of NP
was done by including a PEG-phospholipid conjugate, with or without a targeting ligand
anisamide, in the outer leaflet lipid mixture. The sub-cellular distribution studied in the sigma
receptor positive human H460 lung cancer cells indicated that LCP-II could release more cargo to
the cytoplasm than our previous lipid/protamine/DNA (LPD) formulation, leading to a significant
(~40 fold in vitro and ~4 fold in vivo) improvement in siRNA delivery. Bio-distribution study
showed that LCP-II required more PEGylation for MPS evasion than the previous LPD, probably
due to increased surface curvature in LCP-II.
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1. Introduction
RNA interference (RNAi) therapeutics, such as siRNA, requires a suitable vehicle for in
vivo delivery [1]. An ideal vehicle for cancer therapy should meet at least four major criteria.
They include evasion of the mononuclear phagocytic system(MPS), extravasation from the
blood circulation into the tumor, diffusion through the extracellular matrix to bind with
tumor cells, and escape from the endosome to release the cargo siRNA into the
cytoplasm[2]. Therefore, a well protected nanoparticle (NP) modified with a suitable
targeting ligand is considered a typical siRNA delivery vehicle to the tumor if the NP
diameter is less than 200 nm[3, 4]. Two major types of lipid-based NPs have been developed
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for targeted siRNA delivery, such as lipid nanoparticle (LNP)[5-8] and lipid/polycation/
DNA complex (LPD)[9-11]. Polymers such as transferrin-cyclodextrin polycationare are
also effective [12-14].
To improve the cargo release activity of our previous LPD formulation, we have prepared a
pH-sensitive calcium phosphate (CaP) core to replace the protamine/DNA core in the LPD
formulation [15]. The Lipid/Calcium/Phosphate type I (LCP-I) formulation was protected by
PEG tethered with an anisamide ligand for binding to the sigma receptor over-expressing
tumor cells. LCP-I showed a 4-fold improvement of the silencing effect in vitro compared to
the previous LPD formulation. There was also a significant target gene silencing activity in a
xenograft model with no significant elevation of inflammatory cytokines, i.e., IL-6 and
IL-12, in the blood. However, the CaP core in LCP-I is highly hydrophilic and requires an
un-scalable column method for purification. In addition, many factors on the surface of the
nanoparticle can influence blood residence time and organ-specific accumulation
[16].Therefore, it is desirable that a variety of lipid can be used as the outer leaflet lipid.
Such flexibility in the choice of the lipid can be important for controlling the
pharmacokinetics and tissue distribution properties of the NP.
In the current work, we prepared a novel siRNA delivery vehicle by employing an anionic
phospholipid, dioleoylphosphatidic acid (DOPA), as a pre-coating reagent during the
formation of the nano-sized CaP core in which siRNA was encapsulated. The lipid coating
prevented the CaP core from aggregation during the centrifugal separation step and rendered
it soluble in CHCl3. The resulting NP core was very small (25-30 nm) and contained a
hollow structure. The DOPA layer on the surface of the CaP core also served as the inner
leaflet lipid for the surface lipid bilayer of LCP. Lipids for the outer leaflet could simply be
added into the CaP core solution in CHCl3. Since a PEG-lipid conjugate, with or without a
tethered ligand, could be included in the outer leaflet lipids, it was not necessary to perform
PEGylation of NP by post-insertion [17]. The improved formulation is named Lipid/
Calcium/Phosphate type II (LCP-II). Significantly different from the previous LCP-I
formulation, LCP-II contains an asymmetric lipid structure verified by the measurement of
zeta potential. We report here the preparation, properties, and in vitro and in vivo activity of
this formulation.
2. Materials and Methods
2.1. The preparation of LCP-II NP
The information about the materials is shown in the supplementary information. Figure 1
shows a flow diagram for the preparation of siRNA-entrapped LCP-II NPs. The anionic
lipid coating CaP cores were prepared by a water-in-oil micro-emulsion method. Briefly,
300 μL of 500 mM CaCl2with 100 μL of 2 mg/mL siRNA was dispersed in 15 mL
Cyclohexane/Igepal CO-520 (71/29 V/V) solution to form a very well dispersed water-in-oil
reverse micro-emulsion. The phosphate part was prepared by 300 μL of 25 mM Na2HPO4
(pH=9.0) in a separate 15 mL oil phase. Two hundred μL (20mg/mL)
dioleoylphosphatydicacid (DOPA) in chloroform was added to the phosphate phase. After
mixing the above two solutions for 20 min, 30 mL of absolute ethanol was added to the
micro-emulsion and the mixture was centrifuged at 12,000 g for at least 15 min to remove
cyclohexane and surfactant. After being extensively washed by ethanol 2-3 times, the pellets
were dissolved in 1 mL chloroform and stored in a glass vial for further modification.
For the preparation of LCP-II NPs, 500 μL of CaP core was mixed with 50 μL of 10 mM
DOTAP/Cholesterol (1:1) or DOPC/Cholesterol (1:1), and50 μL of 3 mM DSPE-PEG-2000
or DSPE-PEG-AA. After evaporating the chloroform, the residual lipid was dispersed in 400
μL of 5mM Tris-HCl buffer (pH=7.4) to form LCP-II NPs. The zeta potential and particle
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size of LCP-II NPs was determined in 1 mM KCl by a Malvern ZetaSizer Nano series
(Westborough, MA). All liposomes were prepared by the thin film hydration method and
extruded through a 100 nm polycarbonate membrane. (In the Results and Discussion
section, when either DOTAP or DOPC was mentioned as the outer leaflet lipid, it meant that
DOTAP or DOPC was mixed with the same molar amount of Cholesterol. The preparation
of LCP-I was described previously [15]. Liposome-protamine-DNA (LPD) NP was prepared
as previously described [11]. The details of quantitative detection of trapping efficiency of
siRNA in LCP-II NPs and TEM experiments for the NPs can be found in the supplementary
information.
2.2. Measurement of quenching efficiency of a fluorescence labeled lipid in LCP-II
Rhod-PE was incorporated in the traditional liposomes or in the outer leaflet of LCP-II
coating lipid bilayer. In the case of traditional liposomes, DOPC/Cholesterol/Rhod-PE in the
molar ratio of 1:1:0.01were prepared by the thin film rehydration method and adjusted in 5
mM Tris buffer (pH 7.4) to 20mM of the total lipids. In the case of LCP-II, the preparation
of the core was according to the same protocol described in section 2.2, except that the outer
leaflet lipid was DOPC/Cholesterol/Rhod-PE(1:1:0.01) instead of DOPC/Cholesterol(1:1).
The original fluorescence intensity of the sample was measured by using a fluorometer
(Perkin Elmer, USA) after diluting 20 times. Subsequently, 2 μL of 0.1% trypan blue was
added and the fluorescence intensity was measured again. Finally, 20 μL of 0.1% Triton
X-100 in PBS was added to the above solution and the fluorescence was recorded again.
Triplet samples were used for each group.
2.3. Cellular studies of LCP-II NP
H460 cells (1 × 105 per well) were seeded in 12-well plates (Corning Inc., Corning, NY)
with cover glass for 12 h before experiment. Cells were treated with different formulations
at a concentration of 100 nM for FAM-labeled dsDNA (mimic of siRNA) in serum
containing medium at 37 °C for 3 h. After washed twice with PBS, cells were fixed with
3.8% paraformaldehyde in PBS at room temperature for 10 min, counterstained with DAPI
(Vector Lab, Burlingame, CA), and imaged by using a Leica SP2 confocal microscope. The
details of in vitro luciferase gene silencing study are shown in the supplementary
information.
2.4. Bio-distribution study and in vivo gene silencing study of the LCP-II NP
Female athymic nude mice of age 6-8 weeks were purchased from Charles River
Laboratories (Wilmington, MA). All work performed on animals were in accordance with
and approved by the University of North Carolina Institutional Animal Care and Use
Committee. H460 cells (2×105) with luciferase expression were subcutaneously injected into
the lower back of female nude mice (about 20 g). When the tumor size reached around 600
mm3, mice were intravenously injected with Cy5.5 labeled siRNA in different formulations
at a dose of 0.6 mg/kg. Four h later, mice were sacrificed and tissues were collected
following by imaging under the IVIS Imaging System (Xenogen Imaging Technologies,
Alameda, CA). The image was quantitatively analyzed by the use of the Image J software.
Only the organs of interest were included in the analysis. The details of in vivo luciferase
gene silencing study are shown in the supplementary information.
3. Results and Discussion
3.1. The characterizations of LCP-II
In the preparation of LCP-II, an amphiphilic phospholipid DOPA (see Figure 1) was added
into the phosphate part of the reverse micro-emulsion. DOPA is known to strongly interact
with Caions at the interface[18]. It is expected that the CaP core should be coated with
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DOPA because excess Ca should be available on the core surface. The C18:1 chains of
DOPA were sufficiently hydrophobic such that the coated cores were soluble in a non-
poplar solvent, i.e., CHCl3, but not in a polar solvent, i.e., EtOH. The insolubility of the
coated core in EtOH allowed convenient washing of the cores in EtOH in which excess
surfactants, including free DOPA, was soluble and washed away. The final LCP-II
formulation was examined by TEM (Figure 2). Both images of NP were obtained without
(panel A, C) and with (panel D) negative staining. Since the lipid bilayer is electron
transparent, only the CaP cores of the NPs were imaged without the negative stain. In panel
A, the image of CaP cores without staining showed particles with a high electron intensity in
the outer part but lower intensity in the inner part, suggesting a hollow structure for the CaP
cores. The size of the cores was about 20-25 nm and the inner hole was about 8-12 nm. This
is in contrast with the much larger particle size (~120 nm) for our previous LCP-I
formulation [15]. A table is shown in the supplementary information for comparison. It is
speculated that the CaP precipitation was initiated at the interface of the micro-emulsion to
entrap siRNA. Since the volume of the precipitate is smaller than the volume of water in the
micro-emulsion, a hollow structure would be formed in the CaP cores. A cartoon diagram is
also shown in Figure 2B to indicate the process of CaP precipitate formation. Since DOPA
is not soluble in aqueous solution, it is highly unlikely that DOPA will pack in the center
aqueous core of the hollow CaP core and the detail discussion can be found in
Supplementary Information. The most reasonable location of DOPA is at the surface of the
CaP core which was probably derived from the oil/water interface of the emulsion.
Since the CaP cores were formed in aqueous droplets, the hollow structure of the core
probably would provide opportunity to entrap, at least partially, water soluble drugs for
targeted delivery. The trapping efficiency of siRNA in LCP-II was approximately 40%.
Figure 2D shows the TEM image of LCP-II with uranyl acetate staining. Although the
hollowness of the core was not observed, the coating lipid membrane of the NP could be
seen by negative staining (arrows in Figure 2D). The overall size of LCP-II was about 25-30
nm in diameter, which was a little smaller than the hydrodynamic diameter (40-45nm)
obtained by dynamic light scattering since TEM images were obtained under a dehydrated
condition.
The hydrophobic core coated with DOPA provided a variety of choices for the outer leaflet
lipid in the bilayer surface to make a water soluble NP for intravenous administration of
siRNA. Both neutral lipid, e.g. DOPC, and cationic lipid, e.g. DOTAP, have successfully
served as the outer leaflet lipid together with cholesterol. Whittenton et al has prepared
asymmetric liposomes which have different lipid leaflet compositions [19]. The inner leaflet
was a cationic lipid to encapsulate negatively charged polynucleotides, and neutral lipid was
placed on the outer leaflet to decrease non-specific cellular uptake/toxicity. Similar to this
structure, an asymmetric lipid bilayer coating structure was hypothesized as shown in Figure
1. The core is different between asymmetric liposomes and the proposed nanoparticle. For
an asymmetric liposome, the inside part is aqueous solution. For the proposed nanoparticle
in this paper, the inner leaflet lipid is coated on solid calcium phosphate precipitate.
When CaP core mixed with the additional lipids such as DOTAP, DOPC, Chol and DSPE-
PEG in chloroform, it would not interact with the lipids due to the presence of organic
solvent. The formation of asymmetric bilayer occurred when organic solvent was removed
from the mixture and exposed to an aqueous solution. A similar self-assemble process also
had been used in other phospholipid coating nanoparticles for in vivo imaging [20, 21].
The asymmetric structure was verified by the measurement of zeta potential (Figure 3 A)
and the quenching efficiency of a fluorescence lipid marker (figure 3B). When the CaP cores
were formulated with DOPC as the outer leaflet lipid, the zeta potential was -11 mV, which
Li et al. Page 4













was close to that (5 mV) of pure DOPC liposomes. However, when DOTAP was employed
as the outer leaflet lipid, the surface potential became +55 mV, which was close to that (75
mV) of pure DOTAP liposomes. A control formulation was prepared to coat the CaP core
with DOPA, the same lipid as the inner one. The resulting NPs became highly negatively
charged (-80 mV) which was similar to that (-98 mV) of pure DOPA liposomes. These
results indicated that the surface of the NPs was determined solely by the outer leaflet lipid;
the inner leaflet lipid DOPA had minimal contribution.
Another experiment was also performed by use of a fluorescence lipid, i.e., rhodamine-PE
(Rhod-PE), incorporated into LCP-II or the traditional liposomes. For LCP-II, the labeled
lipid was added to the outer leaflet lipid mix such that it served as a label for only the outer
leaflet of the bilayer, if LCP-II was indeed coated with an asymmetric lipid bilayer
membrane. On the contrary, the fluorescence lipid was randomly distributed between both
the outer and inner leaflets in the case of the traditional liposomes. The distribution of the
fluorescence label in these two different nanoparticle formulations was measured by
quenching with an impermeable dye, trypan blue. The data in Figure 3 B showed that trypan
blue quenched 50% of the fluorescence intensity of the Rhod-PE incorporated in liposomes.
However, 90% of the fluorescence was quenched when Rhod-PE was used to label the outer
leaflet lipid in LCP-II formulation. This is consistent with the predicted asymmetric
structure of the coating lipid membrane of LCP-II. When the structure of both the liposome
and LCP-II was destroyed by the addition of Triton X-100, all of the Rhod-PE would be
accessible and quenchable by trypan blue. Indeed, nearly all fluorescence of Rhod-PE was
quenched in both nanoparticle formulations. The result of this experiment again supported
the asymmetrical structure of the coating lipid bilayer membrane of LCP-II.
It is well known that a PEG layer is necessary to coat the NP to prolong the circulation time
and enhance the tumor uptake via the enhanced permeability and retention (EPR) effect[3,
22, 23]. PEG-lipid conjugates, such as DSPE-PEG and DSPE-PEG-AA, could be readily
added together with the outer leaflet lipid to form LCP-II. No post-insertion protocol for
PEGylation is necessary as commonly done for other lipidic NP formulations [17]. PEG
layer on the surface of the NP effectively shields the charges of the outer leaflet lipid. After
coating with DOTAP and DSPE-PEG as the outer leaflet lipids, the NPs appeared to be
42-50 nm (hydrodynamic diameter) in size with a zeta potential of +5 mV. This is to be
compared with the NPs without DSPE-PEG in which the zeta potential was 55 mV. Thus,
PEGylation performed with our method also effectively shielded the surface charge of NP.
For targeted delivery of siRNA, DSPE-PEG was replaced by DSPE-PEG-AA. The surface
of the NP was covered by a modified anisamide ligand, which contained a secondary
amine[24]. Thus, the presence of the target ligand elevated the zeta potential of LCP-II to
approximately +25 mV.
We have used HPLC to monitor the stability of the LCP-II formulation in terms of the
cleavage of siRNA by serum. The results showed that there was about 5 % of degradation of
siRNA with 1 h incubation. Less than 20% of siRNA degradation was observed even after 5
h.
3.2. Sub-cellular distribution of FAM-dsDNA entrapped in LCP-II and gene silencing
activity of siRNA delivered by LCP-II
To achieve ligand meditated endocytosis of siRNA to cells, anisamide, a compound
specifically binding to the sigma receptor, was tethered to the distal end of DSPE-PEG as a
targeting ligand. FAM-labeled dsDNA as a model for siRNA was entrapped in LCP-II and
incubated with H460 cells for 3h to study the subcellular distribution of the delivered
siRNA. As shown in Figures 4A and 4B, short arrows indicate that FAM-labeled dsDNA
was evenly spread throughout the cytoplasm of H460 cells after anisamide targeting, but not
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when the LCP-II was not tethered with anisamide. On the contrary, long arrows in Figure 4
C showed the punctate distribution of FAM-labeled dsDNA delivered by the targeted LPD.
This difference was probably because the affinity of protamine and nucleic acid in LPD was
too strong to release the cargo to the cytoplasm. The data is consistent with the notion that
LCP-II de-assembles in the acidic endosome and releases its cargo into the cytoplasm. The
cytoplasmic release activity of LCP-I, a formulation similar to LCP-II, was demonstrated by
detecting the increased Ca ion in the cytoplasm by using a Ca-sensitive dye [15].
H460 cells stably expressing the firefly luciferase were used to examine the siRNA delivery
activity of NP. Luciferase siRNA was encapsulated inLPD, LCP-I and LCP-II with either
DOPC or DOTAP as the outer leaflet lipid. All of the NPs were modified with DSPE-PEG-
AA to improve the ligand-meditated endocytosis and the silencing effect on the luciferase
activity was detected after 24 h of the treatment. The dose response curve in Figure 5
showed that the IC50 was 50 and 200 nM in siRNA for LCP-I and LPD, respectively. The
IC50 was 5 nM for LCP-II coated with either DOPC or DOTAP, but control siRNA did not
show a significant silencing effect. The data indicate that the siRNA could effectively
suppress luciferase expression and the potency in siRNA delivery by LCP-II was improved
10-fold as compared to LCP-I, and 40-fold to LPD. From the results, the data also show that
the silencing effect was dependent on the CaP core instead of the outer leaflet lipid. Similar
to LCP-I, the CaP core in LCP-II also dissolves in low pH in the endosome to increase the
osmotic pressure. The swollen endosome finally bursts and releases the entrapped siRNA,
calcium and phosphate into the cytoplasm. Therefore, it does not need cationic lipid to bind
with the negatively charged endosome membrane lipid to release the cargo, causing the
down-regulation efficiency to become outer leaflet lipid independent. In comparison, in vitro
silencing effect of anti-luciferase siRNA formulated inLipofactamine2000®was done. The
IC50 was around 20 nM in siRNA concentration. Higher concentrations of control siRNA
were formulated by LPD and LCP-I in previous publications [9, 15], none of them had any
significant down-regulation effect.
3.3. Tissue Distribution and Tumor Uptake of siRNA
The bio-distribution of siRNA formulated in LCP-II was studied in a xenograft model of
H460 human lung cancer by using Cy5.5-labeled siRNA. We first investigated the effect of
PEG density of LCP-II on bio-distribution. It is well established that a PEG brush on the
surface of NP effectively resists the uptake of NP by RES [3]. Ordinarily, only 5-6%
PEGylated lipid conjugate can be inserted into the surface of liposomes; higher amounts
lead to solubilization of the liposome bilayer and loss of the entrapped cargo [25]. The
stealth liposomes contain about 5.6% surface PEG which is not enough for the formation of
a polymer brush [25]. The membrane/core type of NP could carry higher density of PEG on
the surface due to the presence of the supported bilayer [26]. For our previous LPD
formulation, 10.6 % of DSPE-PEG in the total surface lipid was required to avoid the RES
uptake, but still keep the bilayer structure intact because of the existence of a supported
bilayer [3]. However, in the LCP-II formulation, liver uptake was still significant even 16%
of the DSPE-PEG in the total outer leaflet lipid was employed (Figure 6). With the increased
amount of DSPE-PEG up to 23%, the LCP-II formulation showed less RES uptake and
preferred to accumulate in the tumor (Figure 6).
Quantitative analysis of the bio-distribution data shown in Figure 6 was analyzed by using
the Image J software as described in section 2.6. The results showed that the ratio of tumor/
liver in animals treated with 23% PEG coated LCP-II was 1.58±0.14, while the ones treated
with 16% PEG coated LCP-II was 1.09±0.15 (p=0.03). We conclude that higher levels of
PEGylation of LCP-II favor tumor accumulation in the liver. The reason is probably because
of the smaller particle size (~ 40 nm), and hence higher curvature, of LCP-II as compared to
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LPD (~ 150 nm). For equal densities of PEG, a high curvature surface would allow more
polymer freedom of motion, and therefore less brush activity, than a low curvature surface.
3.4. In vivo luciferase silencing effect
To examine the silencing activity of siRNA delivered by LCP-IIin vivo, luciferase levels in
the H460 xenograft tumor were detected after a single tail vein injection of NP containing
luciferase siRNA (Figure 7).
LCP-II formulations prepared with either DOPC or DOTAP as the outer leaflet lipid were
studied. All formulations contained DSPE-PEG-AA as the targeting ligand. With the siRNA
dose of 0.12 mg/kg, LCP-II prepared with DOPC as the outer leaflet lipid showed no
silencing effect. The formulation containing DOTAP could down-regulate the luciferase
activity to approximately 50% percent when the dose of siRNA was 0.6 mg/kg. Sixty
percent down-regulation could be reached at 1.2 mg/kg of siRNA dose. However, the
luciferase activity did not change if control siRNA was delivered at the same dose. Thus, the
estimated ED50 for LCP-II mediated delivery of siRNA was about 0.6 mg/kg. Compared to
LCP-I (estimated ED50 = 1.2 mg/kg) using the same xenograft tumor system and luciferase
siRNA [15], the ED50 for siRNA delivery showed a modest improvement with LCP-II.
Effective siRNA doses for gene silencing by using other delivery systems are generally
larger than 1 mg/kg [12, 27]. Thus, both LCP NP formulations represent one of the best
delivery vehicles for siRNA to the solid tumor.
There are two widely accepted major mechanisms for NP-mediated cargo release from the
endosome. The first is the proton sponge effect in which cationic polymers containing 2°
and 3° amines increase the osmotic pressure in the acidic endosome by a buffering
effect[28], and cargo release is the result of the endosome bursting [29]. The second is the
ion-pair formation between the positively charged groups of either cationic polymer or lipid
and the negatively charged groups of the endosome membrane [30]. Clustered ion-pairs lead
to relatively large areas of dehydration at the endosome membrane surface, resulting in de-
stabilization of both the endosome membrane and the cationic vector. We have proposed a
third mechanism in which osmotic pressure increase can be the result of CaP dissolution in
the acidic endosome [15]. This mechanism obviously will require a sufficient number of
LCP simultaneously internalized into the same endosome. If so, the release mechanism
would not depend on the outer leaflet lipid. This was apparently the case for the in vitro
condition in which a large number of LCP-II could be delivered to cells at the same time.
Data in Figure 5 support this mechanism in that siRNA delivery by LCP-II containing either
a neutral (DOPC) or a cationic lipid (DOTAP) showed equal silencing effect. However, data
in Figure 7 clearly indicate that the LCP-II containing cationic lipid (DOTAP) delivered
siRNA more efficiently than the one containing neutral lipid (DOPC).Thus, when an
insufficient amount of NP is delivered to the same endosome at the same time, which is
highly likely for the in vivo situation, cationic lipid is still important, probably for the
formation of ion-pairs.
4 Conclusion
CaP core stabilized with DOPA was prepared by water/oil microemulsion and further coated
with cationic or neutral lipid to form LCP-II. The vehicle has a hollow spherical structure
with a size of about 40 nm and possesses an asymmetric lipid bilayer at the surface. With the
targeting ligand anisamide, the new LCP-II showed a 40-fold improved silence activity
compared to the previous LPD formulation. The new NP vehicle effectively delivers siRNA
to solid tumor in a xenograft model. The therapeutic activity of the encapsulated siRNA will
be tested in future experiments.
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The outline for the preparation of LCP-II NP and the structure of DOPA.
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(A), TEM image of CaP cores coated with DOPA. (B), Hypothesis of the CaP core growth.
(C) and (D),TEM images of LCP-II NPs coated with DOTAP and DSPE-PEG without(C)
and with (D) negative staining. Arrows in (D) show lipid bilayer surrounding the CaP core.
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(A) Zeta-potential of different liposome and LCP-II formulations. All lipid compositions
contained equal amount of cholesterol. (B) Fluorescence quenching of Rhod-PE by trypan
blue. N=3.
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Subcellular distribution of FAM-labeled dsDNA (model for siRNA) in H460 cells. Cells
were incubated with 50 nM dsDNA formulated in LCP-II coated with DOTAP targeted with
AA (A), untargeted LCP-II (B), or AA-targeted LPD (C) for 3 h and imaged with confocal
microscopy. Short arrows in (A) indicate spread, even distribution of fluorescently labeled
dsDNA. Long arrows in (C) indicate punctuate distribution of dsDNA.
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In vitro silencing effect of anti-luciferase siRNA formulated in LPD, LCP and LCP-II with
DOTAP (dotted line) and DOPC (solid line) as the outer leaflet lipid. Data indicate that
LCP-II was about 50-fold more active in delivering siRNA than LPD.
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Biodistribution of fluorescence-labeled siRNA delivered by LCP-II coated with DOTAP and
modified with different amounts of DSPE-PEG. LCP-II was coated with either 16 or 23 mol
% of DSPE-PEG and i.v. injected into nude mice bearing human H460 tumor.
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In vivo silencing effect of luciferase siRNA delivered with LCP-II. Mice bearing human
H460 tumor stably expressing luciferase were i.v. injected with LCP-II prepared with either
DOTAP or DOPC, indicated at the top of the figure, as the outer leaflet lipid. Luc: luciferase
siRNA. Con: control siRNA. Numbers in X-axis indicate the injected dose of siRNA in mg/
kg. ** indicates p<0.05.
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